EP1151091A4 - Improved helper dependent vector system for gene therapy - Google Patents

Improved helper dependent vector system for gene therapy

Info

Publication number
EP1151091A4
EP1151091A4 EP00910029A EP00910029A EP1151091A4 EP 1151091 A4 EP1151091 A4 EP 1151091A4 EP 00910029 A EP00910029 A EP 00910029A EP 00910029 A EP00910029 A EP 00910029A EP 1151091 A4 EP1151091 A4 EP 1151091A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
vector system
dependent vector
helper dependent
improved helper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910029A
Other languages
German (de)
French (fr)
Other versions
EP1151091A1 (en
Inventor
Andrew Bett
Volker Sandig
Rima Youil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1151091A1 publication Critical patent/EP1151091A1/en
Publication of EP1151091A4 publication Critical patent/EP1151091A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
EP00910029A 1999-02-04 2000-01-31 Improved helper dependent vector system for gene therapy Withdrawn EP1151091A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11860199P 1999-02-04 1999-02-04
US118601P 1999-02-04
US13813499P 1999-06-08 1999-06-08
US138134P 1999-06-08
PCT/US2000/002405 WO2000046360A1 (en) 1999-02-04 2000-01-31 Improved helper dependent vector system for gene therapy

Publications (2)

Publication Number Publication Date
EP1151091A1 EP1151091A1 (en) 2001-11-07
EP1151091A4 true EP1151091A4 (en) 2002-09-04

Family

ID=26816557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910029A Withdrawn EP1151091A4 (en) 1999-02-04 2000-01-31 Improved helper dependent vector system for gene therapy

Country Status (4)

Country Link
EP (1) EP1151091A4 (en)
JP (1) JP2002535986A (en)
CA (1) CA2360796A1 (en)
WO (1) WO2000046360A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081707A1 (en) * 2000-06-29 2002-06-27 Donna Armentano Methods for helper-dependent adenoviral vector production
US7820441B2 (en) 2000-09-25 2010-10-26 The Regents Of The University Of Michigan Production of viral vectors
US7803365B2 (en) 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
ES2292271B1 (en) 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. AN ADENOVIRUS-ALFAVIRUS HYBRID VECTOR FOR THE EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOR CELLS.
US20100173387A1 (en) * 2006-04-28 2010-07-08 Universitat Autonoma De Barcelona Method for producing adenovirus vectors for gene therapy and dna sequences used therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
WO1997032481A1 (en) * 1996-03-07 1997-09-12 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
WO1997048806A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
WO1998013510A1 (en) * 1996-09-25 1998-04-02 Graham Frank L Improved adenovirus vectors generated from helper viruses and helper-dependent vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
WO1997032481A1 (en) * 1996-03-07 1997-09-12 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
WO1997048806A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
WO1998013510A1 (en) * 1996-09-25 1998-04-02 Graham Frank L Improved adenovirus vectors generated from helper viruses and helper-dependent vectors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GRABLE M ET AL: "ADENOVIRUS TYPE 5 PACKAGING DOMAIN IS COMPOSED OF A REPEATED ELEMENT THAT IS FUNCTIONALLY REDUNDANT", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 64, no. 5, May 1990 (1990-05-01), pages 2047 - 2056, XP000996013, ISSN: 0022-538X *
HARDY S ET AL: "CONSTRUCTION OF ADENOVIRUS VECTORS THROUGH CRE-LOX RECOMBINATION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 3, 1 March 1997 (1997-03-01), pages 1842 - 1849, XP000670223, ISSN: 0022-538X *
ILAN Y ET AL: "Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, no. 6, 1997, pages 2587 - 2592, XP002143015, ISSN: 0027-8424 *
MITTAL SURESH K ET AL: "Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD.", VIROLOGY, vol. 222, no. 2, 1996, pages 299 - 309, XP002196740, ISSN: 0042-6822 *
PARKS R J ET AL: "A HELPER DEPENDENT ADENOVIRUS VECTOR SYSTEM: REMOVAL OF HELPER VIRUS BY CRE-MEDIATED EXCISION OF THE VIRAL PACKAGING SIGNAL", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 24, 26 November 1996 (1996-11-26), pages 13565 - 13570, XP000617948, ISSN: 0027-8424 *
See also references of WO0046360A1 *

Also Published As

Publication number Publication date
WO2000046360A1 (en) 2000-08-10
EP1151091A1 (en) 2001-11-07
CA2360796A1 (en) 2000-08-10
JP2002535986A (en) 2002-10-29

Similar Documents

Publication Publication Date Title
IL150484A (en) Colloid synthetic vectors for gene therapy
GB2351912B (en) Defibrillation system
EP1180160A4 (en) Antibiotic-based gene regulation system
EP1109896A4 (en) Adenovirus formulations for gene therapy
AU2637100A (en) Delivery system and methods for gene therapy
GB9921236D0 (en) Traction support system
IL139936A0 (en) Gene therapy method
EP1175228A4 (en) Gene therapy using tgf-beta
EP1151091A4 (en) Improved helper dependent vector system for gene therapy
HUP0105208A3 (en) Gene therapy-1
IL146332A0 (en) PrP-LIKE GENE
IL148805A0 (en) Gene transfer vectors
GB9924981D0 (en) Gene therapy
GB0008966D0 (en) Vectors for gene therapy
GB9900009D0 (en) Gene therapy
GB0406539D0 (en) Gene therapy
EP1084236A4 (en) Novel adenoviral vectors for gene therapy
EP1215284A4 (en) Tsg-like gene
MXPA01012500A (en) Gene therapy products.
AU4552700A (en) Gene therapy
GB9920837D0 (en) Gene therapy
GB9910587D0 (en) Gene therapy
GB2388323B (en) Defibrillation system
AU7543200A (en) Targeted gene therapy
GB9816775D0 (en) Herpesviral vectors for gene delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020717

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040416

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070301